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INTRODUCTION
S e z a ry syndrome is a distinct clinical variant of ery t h ro-
d e rmic mycosis fungoides (MF) or cutaneous T-cell lym-
phoma (CTCL) in which patients present with circ u l a t i n g
malignant lymphocytes, called Sezary cells, in the peripheral
blood [1–4]. In a recent study of 106 patients with ery t h ro-
d e rmic MF and Sezary syndrome, patients presenting with
.5% circulating Sezary cells had a median survival of 2.6
years [5]. 
A variety of treatments are currently being used for
MF/CTCL, including topically directed therapies such as
total skin electron beam radiation therapy, photochemother-
apy (PUVA), and topical chemotherapy and systemic thera-
pies such as single-agent chemotherapy, retinoids, combina-
tion chemotherapy, interf e ro n -α, extracorporeal pho-
tochemotherapy (photopheresis), and combined modality
regimens [1–4]. Most of these treatments are palliative and
none is considered to have significant curative potential in
patients with advanced disease. Curre n t l y, photophere s i s
with or without interf e ro n -α is the standard treatment for
erthyrodermic MF and Sezary syndrome [6,7].
Ve ry few patients with MF/CTCL have been tre a t e d
with high-dose therapy and bone marrow transplantation
(BMT). In most of these cases, autologous bone marro w
has been used for hematopoietic reconstitution [8,9].
Although feasible, this approach has been associated with a
v e ry high risk of relapse. Herein, we re p o rt our experience
with allogeneic BMT from an unrelated donor in a young
woman with re f r a c t o ry Sezary syndrome. To our knowl-
edge, this is the first patient with Sezary syndrome or
advanced CTCL who has been successfully treated with
allogeneic unrelated donor BMT.
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ABSTRACT
S e z a ry syndrome is a leukemic variant of mycosis fungoides (MF)/cutaneous T-cell lymphoma (CTCL). Bone marro w
transplantation (BMT) from a matched unrelated donor was perf o rmed in a 22-year-old woman with a 10-year hist o ry
of Sezary syndrome who had failed treatment with cort i c o s t e roids, methotrexate, photochemotherapy, photopheres i s ,
h y d ro x y u rea, interf e ro n -α, and cladarabine. At the time of BMT, she had persistent ery t h ro d e rmic skin disease,
a d e n o p a t h y, circulating Sezary cells and bone marrow (BM) involvement. The patient underwent BMT from a 6/6
HLA-matched unrelated male donor in August 1996. A BM biopsy obtained on day 30 after BMT showed no
e v idence of lymphoma and complete male donor engraftment. Her skin lesions resolved within 100 days after trans-
plant. Complete staging studies, including T-cell receptor gene re a rrangement studies perf o rmed at 36 months
p o s t - B M T, showed no evidence of re c u rrent Sezary syndrome. This re p resents her first durable remission since the ini-
tial diagnosis more than 12 years ago. To our knowledge, this is the first patient with re f r a c t o ry Sezary syndro m e
who has been successfully treated with allogeneic unrelated donor BMT. Our results indicate that this modality may
be effective in inducing remission in re f r a c t o ry MF/CTCL, including Sezary syndro m e .
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CASE REPORT
Clinical history
The patient was 12 years old when she presented in
early 1986 with erythodermic follicular mucinosis, leukocy-
tosis, hypereosinophilia, diffuse peripheral adenopathy, and
40% circulating Sezary cells. Immunophenotyping and gene
re a rrangement studies perf o rmed on peripheral blood
showed evidence of a T-cell clonal neoplastic process. Initial
p rednisone therapy was unsuccessful. In July 1986, she
developed worsened leukocytosis and infiltrative skin dis-
ease, fevers, and pro g ressive pulmonary infiltrates. She
received weekly methotrexate but was treated subsequently
with photopheresis and PUVA. The initial clinical observa-
tions and pathologic and molecular diagnostic studies on
this patient were reported in 1988 by LeBoit et al. [10].
In 1991, hydroxyurea and prednisone were administered
to control her blood counts. In 1994, her white blood cell
count became elevated to 54,000/µL in association with
marked eosinophilia, lymphocytosis, and persistent Sezary
cells. A lymph node biopsy showed morphologic and
immunophenotypic findings consistent with a T-cell lym-
phoma. Additionally, cytogenetic studies on the lymph node
tissue revealed clonal karyotypic changes (i.e., trisomy 3 and
a derivative chromosome 23) that have been found in some
T-cell lymphomas. A bone marrow biopsy and aspirate also
showed morphologic evidence of lymphomatous involve-
ment. The patient was started on interferon-α in May 1994
and was maintained on daily doses of 6–9 million units for
.2 years, to which she had a partial response. Interferon-α
was discontinued 2–3 months before BMT, at which time
she received one cycle of cladarabine (2-chlorodeoxyadeno-
sine), with minimal response. 
Disease status bef o re BMT
Clinically, the patient had mild to moderate pruritis. On
physical examination, there were focal areas of confluent
erythema on her abdomen, back, and extremities involving
40–50% of the skin surface area as well as diffuse peripheral
adenopathy measuring 2.0 cm in maximum diameter. Com-
puted tomography scans of the chest, abdomen, and pelvis
showed bilateral axillary and inguinal adenopathy measuring
2.0 cm. 
Peripheral blood showed occasional (,5%) cytologically
atypical lymphoid cells consistent with Sezary cells (Fig. 1).
A bone marrow biopsy and aspirate showed morphologic
evidence of involvement with T-cell lymphoma. Immunohis-
tochemical studies demonstrated cytoplasmic CD3 and
CD45RO expression. Flow cytometry was also perf o rmed on
cells in suspension pre p a red from the bone marrow aspira-
tion. The neoplastic cells expressed the CD2, CD4, CD5,
T C Ra/b, and CD45 antigens and were negative for the sur-
face CD3 and CD7 antigens (Fig. 2). Cytogenetics of bone
m a rrow showed a normal XX kary o t y p e .
Details of BMT
Written informed consent for participation in this study
was obtained before BMT in accordance with the City of
Hope National Medical Center Institutional Review Board
guidelines. The patient received a conditioning regimen of
fractionated total-body irradiation to a total dose of 1320
cGy followed by cyclophosphamide 60 mg/kg (ideal body
weight) for two consecutive days. On 27 August 1996, she
underwent BMT using unmanipulated bone marrow from a
6/6 HLA-matched unrelated 35-year-old male donor. Sero-
logic typing was performed for class I HLA-A, -B, and -C
loci. Molecular typing of class II HLA-DRB1 and -DQ
antigens was done by sequence-specific oligonucleotide
p robe hybridization [11]. The donor and recipient were
s e rologically matched at HLA-A and -B loci and molecu-
larly matched at HLA-DR loci but mismatched at one
HLA-C allele. The patient received 1.031 08 m o n o n u c l e a r
cells per kilogram of body weight. A CD341 cell count was
not obtained. Graft-vs.-host disease (GVHD) pro p h y l a x i s
consisted of cyclosporine A (CSA) and prednisone as well as
methotrexate on days 1, 3, 6, and 11 [11]. 
The patient reached an absolute neutrophil count
.500/mL on day 16 and platelet count .25,000/mL without
subsequent platelet transfusions on day 13. During the
period of neutropenia, she developed fevers that responded
to bro a d - s p e c t rum antibiotics. She subsequently re c o v e re d
from all acute BMT-related toxicities.
F l o w cytometry 
Immunophenotyping was perf o rmed by three-color flo w
cytometric analysis of bone marrow aspirates with a Becton
Dickinson (Mountain Vi e w, CA) FACScan instrument [12]. 
T-cell receptor gene r e a rr a n g ement studies
The presence of a clonal T-cell receptor gene rearrange-
ment was detected at the time of her initial diagnosis and
reported in 1988 by LeBoit et al. at the referring institution
[10]. These investigators used Southern blot analysis of
DNA extracted from peripheral blood involved with 40%
S e z a ry cells to demonstrate the presence of re a rr a n g e d
bands using three different restriction enzymes and a radio-
labeled cDNA probe to the TCR-β gene [10]. In the current
study of a post-BMT remission specimen, re a rr a n g e m e n t s
of the TCR-γ variable 1–8, 9, 10, and 11 genes were ana-
lyzed using the polymerase chain reaction (PCR), as previ-
ously described [13]. 
Figure 1. 
Occasional slightly larger lymphoid cells (Sezary cells) with irregularly folded,
cerebriform nuclei are seen in the patient’s peripheral blood (Wright-Giemsa
stained smear, original magnification 31000).
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RESULTS 
A bone marrow biopsy and aspirate obtained on day 30
showed complete disappearance of lymphoma. Cytogenetics
showed a normal XY karyotype consistent with complete
male donor engraftment. The erythema and induration of
her skin and symptoms of pruritis resolved within the first
100 days posttransplant. Examination of multiple sequential
peripheral blood smears has shown no evidence of circulat-
ing Sezary cells during a 36-month follow-up period. She
developed dermatomal Herpes zoster before day 100 which
was treated with intravenous acyclovir. She had no acute
GVHD or cytomegalovirus disease. Her posttransplant
course has been complicated by the development of chronic
skin GVHD, which is being treated with cyclosporine and
p rednisone. The flare-ups of GVHD involved primarily
sun-exposed areas and did not correlate with previous areas
of involvement by CTCL. Staging studies, including com-
puted tomography scans and routine bone marrow biopsies
p e rf o rmed at regular post-BMT evaluations, show no evi-
dence of recurrent CTCL. 
On physical examination and routine laboratory testing
p e rf o rmed 36 months post-BMT, there was no evidence of
S e z a ry syndrome. Her Karnofsky perf o rmance status is
80–90%. The patient remains free of pruritis. Flow cytom-
e t ry analysis of the patient’s bone marrow before transplan-
tation revealed a population of CD51, CD31/ – cells that
w e re no longer present 29 months after transplantation
(Fig. 2).
I n i t i a l l y, the clonal nature of the patient’s Sezary cells
was demonstrated by Southern blot analysis using a generic
T C R -β p robe (10). Because all T-lymphoid malignancies
with TCR-β re a rrangements also have TCR-γ re a rr a n g e-
ments, which are less heterogenous, we evaluated the
p a t i e n t ’s posttransplant bone marrow (at 36 months) by
PCR using TCR-γ–specific probes (13). No evidence of
TCR-γ clonality was found, indicating the prior clonal pop-
ulation was no longer present (Fig. 3).
DISCUSSION
Mycosis fungoides is a rare type of low-grade T- c e l l
lymphoma involving primarily the skin that can present with
the formation of patch, plaque, and tumor lesions. Advanced
stages of this type of CTCL are associated with dissemina-
tion into lymph nodes and visceral sites, features generally
associated with a poor prognosis. A variant of this disorder
p resents with generalized pruritic ery t h ro d e rma in ~5% of
MF/CTCL patients. Fre q u e n t l y, patients with generalized
e ry t h ro d e rma develop Sezary syndrome, a leukemic mani-
festation of this disease characterized by the presence of
neoplastic T-cells with hyperlobated cere b r i f o rm nuclei
( S e z a ry cells) in the peripheral blood. The prognosis for
Figure 2. 
Flow cytometric immunophenotyping of the 1996 bone marrow specimen involved by lymphoma (A) demonstrates a population of neoplastic T cells that are CD51
with partial loss of CD3 (upper left quadrant). The follow-up specimen obtained in 1999 (B) demonstrates no abnormal T-cell population.
Figure 3. 
Polymerase chain reaction study for T-cell receptor g chain gene rearrange-
ments fail to demonstrate evidence of a monoclonal T-cell population in the
1999 follow-up bone marrow specimen using primer sets designed against all
eleven variable (V) regions of the T-cell receptor g gene. Positive controls for
each primer set are illustrated in the last four lanes on the right. MW, molec-
ular weight.
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patients with Sezary syndrome is generally poor, with a
median survival of ,3 years [5].
Most patients with MF/CTCL are in their sixth decade
of life. A recent study of prognostic factors in advanced-stage
e ry t h ro d e rmic MF and Sezary syndrome re p o rted a mean age
of 62 years (range 24–87) in the 106 patients analyzed [5].
T h e re are few re p o rts of MF/CTCL developing in childre n
and adolescents [14–18]. Clinical presentations were primar-
ily patch and plaque stage disease, but rare instances of tumor
stage, granulotamous Slack disease, and classic Sezary syn-
d rome have also been re p o rted, suggesting that MF/CTCL
in young patients also re p resents a heterogeneous spectru m
of disease. Long-term follow-up results of therapy in this sub-
g roup of patients are not available, but pre s u m a b l y, their
p rognostic variables are similar to the typical older patients
with MF/CTCL. Because these disorders have a marked
p ropensity for relapse and are generally considered to be
incurable with conventional treatments, it is likely that
younger patients afflicted with MF/CTCL will suffer re d u c e d
longevity as a consequence of their malignancy.
The patient re p o rted herein presented with several
unique clinical features. In 1986, at the age of 12, she devel-
oped follicular mucinosis, a cutaneous disorder which by
itself is not considered to be a malignant process, along
with immunophenotypic and immunogenetic evidence of
clonal neoplastic Sezary cells of T-cell lineage in the
peripheral blood [10]. The natural history of her illness was
c h a r a c t e r i stic of Sezary syndrome with the development of
peripheral adenopathy, leukocytosis, eosinophilia, ery t h ro-
d e rma, alopecia, pulmonary infiltrates, and circ u l a t i n g
malignant T-cells. She failed multiple conventional thera-
pies aimed at controlling her disease including pre d n i s o n e ,
m e t h o t rexate, hydro x y u rea, photopheresis, interf e ro n -α,
P U VA, and cladarabine. After more than 10 years of re c e i v-
ing these standard therapies, the patient had persistent dis-
ease involving her skin, lymph nodes, peripheral blood, and
bone marro w.
Bone marrow transplantation, once used only after failure
of conventional types of therapy, is now the pre f e rred ther-
apy for many malignant hematologic disorders [19,20]. Allo-
geneic BMT has been most commonly used for the eradica-
tion of acute and chronic leukemia. For some hematologic
diseases such as aplastic anemia, chronic myelogen o u s
leukemia, myelodyplasia and acute leukemia in re l a p s e ,
c h ronic lymphocytic leukemia, and leukemic phase of
malignant lymphoma, allogeneic BMT from a matched sib-
ling or unrelated donor is the only viable potentially cura-
tive therapeutic option.
Allogeneic BMT has been re s e rved primarily for
patients with advanced or multiply re c u rrent “poor- r i s k ”
lymphoma who are not considered to be appropriate can-
didates for autologous transplantation [21–24]. Relapse
rates after allogeneic BMT are substantially lower com-
p a red with autologus transplantation in patients with heav-
ily pre t reated low-grade lymphoma, most likely due to a
graft-vs.-lymphoma (GVL) effect [22,25–27]. Patients
receiving allogeneic BMT have a higher risk of tre a t m e n t -
related mort a li t y, especially if an unrelated donor is used,
but a lower risk of relapse and improved disease-free sur-
vival [27–29]. These studies suggest that allogeneic BMT
may be potentially curative in selected patients with
advanced lymphoma, particularly those with low-grade his-
tologies [25–27,29]. Unlike results using autologous trans-
plants, there are very few relapses after 3 years in this
g roup of patients. 
Kuzel et al. [30] have re p o rted pre l i m i n a ry results of
allogeneic BMT in two patients with tumor-stage MF who
had failed a variety of topically directed and systemic thera-
pies. Both patients were in remission at 200 and 101 days
posttransplant at the time of this report. Further investiga-
tion on the use of allogeneic BMT in the treatment of
patients with advanced MF/CTCL is warranted, inasmuch
as a GVL effect is known to accompany GVHD in patients
with lymphoma [22]. Because GVHD frequently occurs in
the skin, the most common site of involvement of
MF/CTCL, it is also intriguing to consider whether this
phenomenon may contribute to the efficacy of BMT in the
treatment of these disorders. In the patient presented in this
report, there was no correlation between the distribution of
cutaneous chronic GVHD and sites of previous lymphoma-
tous skin involvement.
CSA, a potent inhibitor of T-cell activation and expan-
sion, is commonly used for the prevention and tre a t m e n t
of GVHD after BMT. Cooper et al. [31] conducted a phase
II study of CSA for the treatment of re f r a c t o ry T-cell lym-
phomas, including CTCL. The dose of CSA used in this
study was higher (7.5 mg/kg twice a day) than the dose
used in BMT, which is usually 5.0 mg/kg twice a day up to
day 83, followed by tapering doses thereafter [11]. None of
the patients with peripheral T-cell lymphoma re s p o n d e d ,
but two of 11 patients with CTCL achieved a temporary
clinical complete response. In both patients, disease activ-
ity re c u rred within a week after withdrawal of therapy.
These observations suggest that CSA exerted a cytostatic
rather than a cytotoxic effect or, altern a t i v e l y, that CSA
t reatment resulted in clinical improvement by decre a s i n g
an inflammatory response secondary to the CTCL cells.
Although another response was seen after CSA was re a d-
m i n i s t e red at a lower dose, both patients eventually
became resistant to CSA and had disease pro g re s s i o n .
It is unlikely that the remission achieved by our patient
is attributable to the use of CSA. The trial by Cooper et al.
indicates that the response rate and duration of response to
CSA are disappointingly low in CTCL. None of the
patients in their study had evidence of Sezary syndro m e .
M o re o v e r, the remission status in our patient has been
documented by immunophenotypic and T-cell re c e p t o r
gene re a rrangement studies at 36 months post-BMT, and
it is unlikely that this clinical and molecular re m i s s i o n
could be achieved with an agent that is cytostatic rather
than cytotoxic.
MF/CTCL generally has a long natural history and ini-
tially behaves as a low-grade neoplasm. Our patient had
advanced disease for .10 years without ever having achieved
a clinical remission before BMT despite multiple therapies.
Based on this case and the experience of allogeneic BMT for
other patients with low-grade lymphoma, we suggest that
younger patients with advanced MF/CTCL and Sezary syn-
d rome who fail standard therapies such as photopheresis or
i n t e rf e ro n -α should be considered for allogeneic BMT fro m
a sibling or unrelated donor. Longer follow-up will be
re q u i red to determine the durability of remission after BMT.
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